StockNews.AI
CVKD
StockNews.AI
1 min

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

1. Cadrenal reports Q3 2025 financial results, showing a net loss of $2.7 million. 2. Progress is made in tecarfarin's clinical development for anticoagulation therapy. 3. The company expands by acquiring eXIthera's Factor XIa inhibitors portfolio. 4. Cash and cash equivalents stand at approximately $3.9 million as of September 30. 5. CEO emphasizes ongoing discussions for developing strategic partnerships to enhance offerings.

11m saved
Insight
Article

FAQ

Why Bullish?

The clinical progress of tecarfarin and the acquisition of frunexian could signal future growth. Historical examples show that drug development milestones can positively influence stock prices, particularly in biotech sectors.

How important is it?

The report provides insight into advancements and strategic positioning that are crucial for future growth, demonstrating both operational progress and plans that may entice investor confidence.

Why Long Term?

As clinical trials progress and potential market introductions loom, they may generate increased investor interest and confidence over time. The potential long-term efficacy of tecarfarin and frunexian could reshape market positions.

Related Companies

ABTPTGXBMY
PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturing of tecarfarin drug product in accordance with current good manufacturing practices (cGMP).Ongoing activities in support of a single-site U.S. Phase 2 study of tecarfarin in LVAD patients as part of the collaboration agreement with Abbott.Investigator discussions for a potential multi-site Phase 2 study of tecarfarin in dialysis patients already treated with warfarin. Expanded Cadrenal’s portfolio through the acquisition of the assets of eXIthera Pharmaceuticals, including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors, in September 2025. The lead asset, frunexian, is a first-in-class, Phase 2-ready IV Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices plays a significant role, such as cardiopulmonary bypass, catheter thrombosis, and other blood-contacting implanted cardiac devices. “We have uniquely positioned ourselves to address gaps in anticoagulation treatment of multiple indications through the development of two differentiated anticoagulants (tecarfarin and frunexian) while benefitting from pathways that provide clear regulatory designations,” commented Quang X. Pham, Chairman & CEO. “Having multiple pathways has allowed us to be prudent and flexible in our strategic approach to achieving critical development milestones as we look to advance our therapies for patients where conventional anticoagulation does not provide sufficient safety or efficacy.”   “Our focus as we finish 2025 is the progression of tecarfarin into clinical applications where significant anticoagulation challenges exist,” Pham continued. “We are in discussions with key partners to move forward a development strategy which we believe is critical to the broader anticoagulation industry to address gaps in care and unlock key value for shareholders.” Third Quarter 2025 Financial Highlights Research and development expenses for the quarter ended September 30, 2025, were $0.7 million compared to $0.8 million for the same period in 2024. General and administrative expenses for the quarter ended September 30, 2025, were $2.0 million compared to $1.7 million for the same period in 2024. Cadrenal reported a net loss of $2.7 million for the quarter ending September 30, 2025, compared to $2.4 million for the same period in 2024. On September 30, 2025, Cadrenal had cash and cash equivalents of $3.9 million. The Company had approximately 2.1 million shares of common stock outstanding as of September 30, 2025. About Cadrenal Therapeutics, Inc. Cadrenal Therapeutics, Inc. is a biopharmaceutical company with a mission to develop novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy. We bridge these gaps by developing novel and differentiated anticoagulants, or blood thinners, designed to provide greater predictability, increased stability, more precise control, and fewer bleeding complications. We currently have two clinical-stage assets: tecarfarin, an oral vitamin K antagonist (VKA) for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. By targeting underserved patient populations and advancing therapies designed for both chronic and acute use, we aim to reshape standards of care in anticoagulation. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn. Safe Harbor Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include the Company’s ability to develop transformative therapeutics to overcome current gaps in anticoagulation therapy, the Company’s ongoing activities supporting a single-site U.S. Phase 2 study of tecarfarin in LVAD patients as part of the collaboration agreement with Abbott; the potential initiation of a multi-site Phase 2 study of tecarfarin in dialysis patients already treated with warfarin; the Company being uniquely positioned to address gaps in anticoagulation treatment of multiple indications through development of two differentiated anticoagulants (tecarfarin and frunexian); the Company achieving critical development milestones; the progression of tecarfarin into clinical applications where significant anticoagulation challenges exist; moving forward with a development strategy with key partners; addressing gaps in care and unlocking key value for shareholders. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to develop novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy; the Company’s ability to achieve critical development milestones and commence clinical trials as anticipated; the Company having sufficient funding to achieve its clinical goals; the Company’s ability to target underserved patient populations and advance therapies designed for both chronic and acute use and to reshape standards of care in anticoagulation and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise. For more information, please contact: Lytham Partners, LLCRobert Blum, Managing Partner602-889-9700CVKD@lythampartners.com Cadrenal Therapeutics, Inc. Balance Sheets          September 30, 2025  December 31,   (unaudited)  2024 Assets:      Current assets:      Cash and cash equivalents$3,860,082  $10,017,942  Interest receivable 12,791   38,153  Prepaid expenses and other current assets 116,015   42,257  Deferred offering costs 90,838   14,445  Total current assets 4,079,726   10,112,797  Property, plant and equipment, net 5,729   6,944  Other assets 2,167   3,792  Total assets$4,087,622  $10,123,533  Liabilities and Stockholders' Equity:      Current liabilities:      Accounts payable$614,127  $1,502,468  Accrued liabilities 738,548   1,181,490  Total current liabilities 1,352,675   2,683,958  Total liabilities 1,352,675   2,683,958  Stockholders equity:      Preferred stock, $0.001 par value, 7,500,000 shares authorized, no shares issued and outstanding at September 30, 2025 and December 31, 2024 -   -  Common stock, $0.001 par value; 75,000,000 shares authorized, 2,059,754 shares issued and outstanding as of September 30, 2025; 1,782,486 shares issued and outstanding as of December 31, 2024 2,059   1,782  Additional paid-in capital 38,654,043   33,160,576  Accumulated deficit (35,921,155)  (25,722,783) Total stockholders equity 2,734,947   7,439,575  Total liabilities and stockholders equity$4,087,622  $10,123,533   CADRENAL THERAPEUTICS, INC.STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS             Three Months Ended September 30, Nine Months Ended September 30,  2025 2024 2025 2024Operating expenses:          General and administrative expenses$2,044,937  $1,674,905 $6,955,907  $4,013,336 Research and development expenses 688,465   784,646  3,433,845   2,667,382 Depreciation expense 401   407  6,319   1,473 Total operating expenses 2,733,803   2,459,958  10,396,071   6,682,191 Loss from operations (2,733,803)  (2,459,958) (10,396,071)  (6,682,191)Other income          Interest and dividend income 48,098   52,129  197,699   218,092 Total other income 48,098   52,129  197,699   218,092 Net loss and comprehensive loss$(2,685,705) $(2,407,829)$(10,198,372) $(6,464,099)           Net loss per common share, basic and diluted (1)$(1.31) $(2.18)$(5.23) $(5.24)Weighted average number of common shares used in computing net loss per common share, basic and diluted (1) 2,044,033   1,104,005  1,950,703   1,234,672 

Related News